Research work · 2006

[FOLFOX].

Hideyuki Mishima, Masakazu Ikenaga, Toshimasa Tsujinaka, Masayoshi Yasui, Masaki Kashiwazaki, Michihiko Miyazaki, Motohiro Hirao, Kazumasa Fujitani, Shouji Nakamori

PubMed

Abstract

In metastatic colorectal cancer, a combination of Leucovorin (LV) and fluorouraci (l FU) with oxaliplatin (FOLFOX) is a standard first-line regimen. The two limiting toxicities of FOLFOX are neutropenia and the specific reversible sensory neuropathy of oxaliplatin. The cumulative neurotoxicity often requires therapy to be stopped. Immediate hypersensitive reactions (anaphylaxis) have been noted as often as to 0.6 percent. We should pay sufficient attention to side effects of FOLFOX.